D. Mavroudis

E. Sanidas, V. Georgoulias, D. Mavroudis, 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial.

S. Agelaki, V. Georgoulias, I. Boukovinas, 2010 .

A new paradox for pCR in BRCA mutation carriers

D. Mavroudis, K. Rounis, 2019, Translational cancer research.

Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance.

I. Vlachonikolis, D. Mavroudis, V. Georgoulias, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).

V. Georgoulias, I. Boukovinas, N. Malamos, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy.

E. Winer, T. Fehm, C. Hudis, 2020, Journal of the National Cancer Institute.

A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer

M. Spiliotaki, G. Kallergi, V. Georgoulias, 2017, Cellular Physiology and Biochemistry.

Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer

E. Lianidou, D. Mavroudis, V. Georgoulias, 2013, British Journal of Cancer.

Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance.

S. Agelaki, V. Georgoulias, M. Perraki, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Genome-wide association study of germline variants and breast cancer-specific mortality

A. Whittemore, W. Willett, S. Cross, 2019, British Journal of Cancer.

Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.

S. Agelaki, V. Georgoulias, D. Mavroudis, 2007, Digestive diseases.

WITHDRAWN: Irinotecan plus Weekly 5-Fluorouracil and Leucovorin as Salvage Treatment for Patients with Metastatic Colorectal Cancer: A Phase II Trial

S. Agelaki, V. Georgoulias, D. Mavroudis, 2007, Digestive Diseases.

A Dose Escalating Study of Oxaliplatin and High Dose Weekly Leucovorin and 5-Fluorouracil in Patients with Advanced Solid Tumors

S. Agelaki, V. Georgoulias, D. Mavroudis, 2005, Cancer investigation.

Combination of Irinotecan (CPT-11) plus 5-Fluorouracil and Leucovorin (FOLFIRI Regimen) as First Line Treatment for Elderly Patients with Metastatic Colorectal Cancer: A Phase II Trial

S. Agelaki, V. Georgoulias, D. Mavroudis, 2005, Oncology.

Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.

S. Agelaki, V. Georgoulias, N. Athanasiadis, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Irinotecan (CPT-11) in Combination With Infusional 5-Fluorouracil and Leucovorin (de Gramont Regimen) as First-Line Treatment in Patients With Advanced Colorectal Cancer: A Multicenter Phase II Study

V. Georgoulias, N. Ziras, D. Mavroudis, 2002, American journal of clinical oncology.

Oxaliplatin in Combination with Infusional 5-Fluorouracil and Leucovorin Every 2 Weeks as First-Line Treatment in Patients with Advanced Colorectal Cancer: A Phase II Study

V. Georgoulias, N. Malamos, G. Samonis, 2001, Oncology.

Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.

V. Georgoulias, I. Boukovinas, N. Ziras, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A Dose-Finding Study of Irinotecan (CPT-11) plus a Four-Day Continuous 5-Fluorouracil Infusion in Advanced Colorectal Cancer

V. Georgoulias, D. Mavroudis, J. Souglakos, 2001, Oncology.

Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients.

Ulas Bagci, Vasilios Georgoulias, Georgios Z Papadakis, 2017, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Running title : CTCs and staging in MBC

T. Fehm, C. Caldas, J. Reis-Filho, 2018 .

Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study

M. Kontogianni, S. Agelaki, D. Mavroudis, 2021, Translational lung cancer research.

Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study.

S. Agelaki, V. Georgoulias, D. Mavroudis, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer

Harris Markomanolaki, G. Kallergi, V. Georgoulias, 2015, PloS one.

Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history.

V. Baracos, Z. Giannousi, V. Georgoulias, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.

S. Agelaki, V. Georgoulias, P. Malliotakis, 2000, Lung cancer.

A Dose Escalation Study of Gemcitabine plus Pemetrexed Administered Biweekly in Patients with Solid Tumors

S. Agelaki, D. Mavroudis, V. Georgoulias, 2007, Oncology.

Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.

S. Agelaki, V. Georgoulias, G. Samonis, 2001, European journal of cancer.

Trastuzumab versus observation in women with early breast cancer and CK-19 mRNA-positive circulating tumor cells (CTCs): A pilot randomized phase II study.

S. Agelaki, G. Kallergi, V. Georgoulias, 2010 .

Randomized phase III trial comparing the sequential administration of docetaxel followed by epirubicin plus cyclophosphamide versus FE75C as adjuvant chemotherapy in axillary lymph node-positive breast cancer

A. Adamou, K. Syrigos, V. Georgoulias, 2008 .

Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes

S. Agelaki, V. Georgoulias, K. Stylianou, 2001, British Journal of Cancer.

Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.

S. Agelaki, V. Georgoulias, N. Malamos, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

S. Cross, M. Beckmann, P. Fasching, 2021, British Journal of Cancer.

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

T. Fehm, C. Caldas, J. Reis-Filho, 2014, The Lancet. Oncology.

Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation

T. Fehm, C. Caldas, S. Dawson, 2022, The oncologist.

A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer.

V. Georgoulias, I. Boukovinas, N. Malamos, 2013, Breast.

Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.

S. Agelaki, D. Mavroudis, V. Georgoulias, 2000, American journal of clinical oncology.

A Phase I Clinical Trial of Topotecan Given Every 2 Weeks in Patients with Refractory Solid Tumors

S. Agelaki, V. Georgoulias, D. Mavroudis, 2001, Oncology.

The Role of Vitamin D Receptor Gene Polymorphisms in Colorectal Cancer Risk

M. Tzardi, D. Mavroudis, J. Souglakos, 2019, Cancers.

Prognostic Value of KRAS Mutations in Colorectal Cancer Patients

M. Karamouzis, M. Tzardi, A. Voutsina, 2022, Cancers.

A Dose Escalation Study of Biweekly Oral Vinorelbine and Gemcitabine in Patients with Solid Tumors

S. Agelaki, M. Ignatiadis, V. Georgoulias, 2007, Oncology.

Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors

A. Tsirigos, H. Gogas, A. Bamias, 2021, Cancer Immunology Research.

Genome-wide association study of germline variants and breast cancer-speci ﬁ c mortality

A. Whittemore, M. Beckmann, A. Talhouk, 2019 .

Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte‐mediated inhibition of CFU‐GM and alterations in T‐cell receptor Vβ profiles

A. Barrett, N. Hensel, M. Stetler-Stevenson, 1998, British journal of haematology.

Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study

Jack A. Taylor, S. Cross, M. Beckmann, 2022, British Journal of Sports Medicine.

Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG).

M. Dimopoulos, A. Papatsoris, M. Karamouzis, 2016, Clinical genitourinary cancer.

Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group.

V. Georgoulias, I. Boukovinas, N. Ziras, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Systemic Chemotherapy in Urothelial Cancer Introduction

M. Dimopoulos, A. Papatsoris, M. Karamouzis, 2022 .

A dose escalation study of weekly docetaxel in patients with advanced solid tumors

S. Agelaki, V. Georgoulias, G. Samonis, 2000, Cancer Chemotherapy and Pharmacology.

Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.

S. Agelaki, V. Georgoulias, D. Mavroudis, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer.

V. Georgoulias, D. Mavroudis, J. Souglakos, 2003, International journal of radiation oncology, biology, physics.

ISO-CC-005; A phase I/II study of arfolitixorin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer.

V. Georgoulias, T. Guren, G. Carlsson, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A Real-world Multicenter Prospective Study of Everolimus in Pancreatic Neuroendocrine Tumors: The ‘PROTOR’ Study

C. Andreadis, D. Mavroudis, K. Pazaitou-Panayiotou, 2022, AntiCancer Research.

Native valve Aspergillus endocarditis in two patients with aplastic anaemia

A. Skiada, D. Mavroudis, G. Petrikkos, 2006, Scandinavian journal of infectious diseases.

Investigation of Microbial Translocation, TLR and VDR Gene Polymorphisms, and Recurrence Risk in Stage III Colorectal Cancer Patients

M. Tzardi, D. Mavroudis, J. Souglakos, 2022, Cancers.

Fulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trials.

V. Georgoulias, G. Casazza, A. Valachis, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.

Jaana M. Hartikainen, M. Beckmann, P. Fasching, 2021, The New England journal of medicine.

Investigating the Role of CTCs with Stem/EMT-like Features in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate

S. Agelaki, D. Mavroudis, M. Papadaki, 2022, Cancers.

The graft‐versus‐leukemia effect

D. Mavroudis, J. Barrett, 1996, Current opinion in hematology.

Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer

M. Tzardi, E. Stathopoulos, V. Georgoulias, 2020, AntiCancer Research.

Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen

A. Barrett, N. Hensel, D. Mavroudis, 1996, British journal of haematology.

Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab

S. Agelaki, D. Mavroudis, K. Michaelidou, 2022, Cancers.

Nonneutropenic febrile episodes associated with docetaxel‐based chemotherapy in patients with solid tumors

V. Georgoulias, G. Samonis, S. Agelaki, 2002, Cancer.

Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial.

V. Georgoulias, G. Samonis, D. Mavroudis, 2001, Lung cancer.

Final results of weekly paclitaxel and carboplatin plus bevacizumab as first-line treatment of triple-negative breast cancer. A multicenter phase I-II trial by the Hellenic Oncology Research Group

S. Agelaki, V. Georgoulias, D. Mavroudis, 2016 .

Endovascular Treatment of Malignant Superior Vena Cava Syndrome through Upper-Limb Access: A Comparison between Venous-Dedicated and Conventional Stents.

N. Kontopodis, D. Mavroudis, S. Charalambous, 2020, Journal of vascular and interventional radiology : JVIR.

Reporting Liver Cancer Trends in the Island of Crete, Greece: Results from a Geo-Epidemiological Study

C. Lionis, D. Sifaki-Pistolla, D. Mavroudis, 2022, International journal of environmental research and public health.

Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer.

V. Georgoulias, N. Karachaliou, D. Mavroudis, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: A preliminary report.

K. Syrigos, V. Georgoulias, I. Boukovinas, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of circulating miRNAs in detecting metastasis and having prognostic significance in metastatic breast cancer.

G. Markakis, S. Agelaki, D. Mavroudis, 2018 .

Comparison of HER2 detection methods between central and regional laboratories in Greece.

G. Aravantinos, N. Malamos, G. Fountzilas, 2007, Clinical breast cancer.

A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.

M. Socinski, K. Syrigos, D. Mavroudis, 2019, Lung cancer.

Salmonella enterica Pneumonia in a Patient with Lung Cancer

G. Samonis, V. Georgoulias, D. Mavroudis, 2003, Journal of Clinical Microbiology.

Transient Fungemia Due to Rhodotorula rubra in a Cancer Patient: Case Report and Review of the Literature

G. Samonis, V. Georgoulias, D. Mavroudis, 2001, Infection.

Bloodstream Infections in Patients with Solid Tumors: Associated Factors, Microbial Spectrum and Outcome

G. Samonis, D. Kontoyiannis, V. Georgoulias, 2004, Infection.

A case of herpes simplex-associated encephalitis after brain irradiation for lung cancer metastases.

D. Mavroudis, E. Papadaki, D. Kofteridis, 2014, Anticancer research.

Merkel Cell Carcinoma—Update on Diagnosis, Management and Future Perspectives

K. Kalpakis, D. Mavroudis, K. Krasagakis, 2022, Cancers.

Genome-wide association study of germline variants and breast cancer-specific mortality

A. Whittemore, W. Willett, S. Cross, 2019, British Journal of Cancer.

Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes

M. Beckmann, N. Camp, Jingmei Li, 2022, JAMA oncology.

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

Michael Jones, Peter Kraft, Arnaud Droit, 2017, Nature Genetics.

Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry

Jane E. Carpenter, Jack A. Taylor, M. Beckmann, 2023, Genome Medicine.

Transcriptome ‐ wide association study of breast cancer risk by estrogen ‐ receptor status

Jack A. Taylor, W. Chung, S. Cross, 2020 .

Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer.

E. Lianidou, E. Stathopoulos, V. Georgoulias, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Genetics.

TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic Implications

S. Agelaki, D. Mavroudis, K. Michaelidou, 2022, Cancers.

Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer

S. Agelaki, D. Mavroudis, A. Koutsopoulos, 2020, Cancers.

Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?

D. Mavroudis, J. Souglakos, M. Sfakianaki, 2020, Cancers.

Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry

N. Girard, K. Samitas, D. Planchard, 2022, JTO clinical and research reports.

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

K. Syrigos, K. Syrigos, G. Samonis, 2006, British Journal of Cancer.

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Communications.

Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer

G. Markakis, M. Spiliotaki, Christoforos Nikolaou, 2018, Breast Cancer Research.

Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy

S. Agelaki, D. Mavroudis, K. Rounis, 2020, Cancers.

Prognostic and Predictive Significance of Pharmacogenetic Analysis in Patients with Carcinomas of Unknown Primary (CAUP)

N. Pavlidis, G. Pentheroudakis, V. Georgoulias, 2012 .

Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers.

I. Vlachonikolis, M. Perraki, E. Lianidou, 2003, Anticancer research.

Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study

M. Tzardi, A. Kalykaki, D. Mavroudis, 2020, Cancers.

PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer

Georgios S. Ioannidis, A. Voutsina, D. Mavroudis, 2014, British Journal of Cancer.

Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer.

I. Vlachonikolis, D. Mavroudis, V. Georgoulias, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study

I. Tsamardinos, S. Agelaki, D. Mavroudis, 2021, PloS one.

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC

E. Stathopoulos, A. Voutsina, D. Mavroudis, 2008, British Journal of Cancer.

‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer

E. Stathopoulos, A. Voutsina, S. Murray, 2007, British Journal of Cancer.

A phase I-II trial of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with advanced ovarian cancer (AOC)

V. Georgoulias, A. Kalykaki, D. Mavroudis, 2004 .

Resectable Colorectal Cancer: Current Perceptions on the Correlation of Recurrence Risk, Microbiota and Detection of Genetic Mutations in Liquid Biopsies

M. Tzardi, D. Mavroudis, C. Tsagkaris, 2021, Cancers.

Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk

Jane E. Carpenter, M. Beckmann, A. Børresen-Dale, 2020, Scientific Reports.

Evaluation of Microsatellite Instability Molecular Analysis versus Immuno-Histochemical Interpretation in Malignant Neoplasms with Different Localizations

M. Tzardi, D. Mavroudis, J. Souglakos, 2023, Cancers.

A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.

S. Agelaki, V. Georgoulias, G. Samonis, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.

V. Georgoulias, D. Mavroudis, S. Kakolyris, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer

S. Agelaki, D. Mavroudis, C. Papadaki, 2019, Oncotarget.

International real-world study of DLL3 expression in patients with small cell lung cancer.

F. Rojo, F. Penault-Llorca, P. Pauwels, 2020, Lung cancer.

Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma.

D. Mavroudis, A. Matikas, 2015, Future oncology.

Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

S. Cross, M. Beckmann, P. Fasching, 2021, Breast Cancer Research.

Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

V. Georgoulias, S. Agelaki, D. Mavroudis, 2021, International journal of molecular sciences.

Circulating miRNAs as Potential Biomarkers in Prostate Cancer Patients Undergoing Radiotherapy

Christoforos Nikolaou, G. Sourvinos, D. Mavroudis, 2021, Cancer management and research.

Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element

Jack A. Taylor, S. Cross, M. Beckmann, 2021, American journal of human genetics.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

T. Fehm, A. Rademaker, C. Caldas, 2019, Critical reviews in oncology/hematology.

Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer

V. Georgoulias, E. Stathopoulos, D. Mavroudis, 2010, British Journal of Cancer.

Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study.

S. Agelaki, V. Georgoulias, N. Ziras, 2000, European journal of cancer.

Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer

S. Agelaki, D. Mavroudis, K. Mavridis, 2020, Cells.

Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis

M. Beckmann, P. Fasching, A. Olshan, 2021, Scientific Reports.

CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies

C. Dunbar, D. Couriel, E. Read, 1996 .

Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.

S. Agelaki, V. Georgoulias, N. Malamos, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes.

M. Perraki, M. Kafousi, E. Stathopoulos, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.

V. Georgoulias, G. Samonis, D. Mavroudis, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mendelian randomisation study of smoking exposure in relation to breast cancer risk

Jack A. Taylor, S. Cross, M. Beckmann, 2021, British Journal of Cancer.

Phase I Study of Paclitaxel (Taxol) and Pegylated Liposomal Doxorubicin (Caelyx) Administered Every 2 Weeks in Patients with Advanced Solid Tumors

S. Agelaki, V. Georgoulias, G. Samonis, 2002, Oncology.

Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study.

V. Georgoulias, D. Mavroudis, P. Cordopatis, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase I Study of the Optimized Cryptic Peptide TERT572Y in Patients with Advanced Malignancies

I. Miconnet, P. Kanellou, M. Spyropoulou, 2006, Oncology.

Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium

S. Cross, M. Beckmann, P. Fasching, 2021, Cancer Epidemiology, Biomarkers & Prevention.

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.

H. Gogas, G. Fountzilas, D. Skarlos, 2003, Clinical breast cancer.

Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group

H. Gogas, C. Markopoulos, G. Fountzilas, 2005, Breast Cancer Research and Treatment.

A Dose-Escalation Study of Pegylated Liposomal Doxorubicin and Oxaliplatin in Patients with Advanced Solid Tumors

S. Agelaki, V. Georgoulias, A. Kalykaki, 2007, Oncology.

Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis.

A. Valachis, D. Mauri, V. Georgoulias, 2011, Breast.

Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk.

S. Cross, M. Beckmann, P. Fasching, 2020, American journal of human genetics.

PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer

M. Tzardi, D. Mavroudis, J. Souglakos, 2020, Cancers.

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

W. Chung, M. Beckmann, P. Fasching, 2019, npj Breast Cancer.

CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

Jane E. Carpenter, Jack A. Taylor, S. Cross, 2021, British Journal of Cancer.

FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women

W. He, M. Beckmann, N. Camp, 2023, European Journal of Human Genetics.

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials

V. Georgoulias, N. Patsopoulos, A. Valachis, 2010, Breast Cancer Research and Treatment.

ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

V. Georgoulias, A. Voutsina, S. Agelaki, 2015, Cancer investigation.

Human G‐CSF‐mobilized CD34‐positive peripheral blood progenitor cells can stimulate allogeneic T‐cell responses: implications for graft rejection in mismatched transplantation

N. Hensel, A. Raptis, R. Childs, 1999, British journal of haematology.

A Prognostic Role for Circulating microRNAs Involved in Macrophage Polarization in Advanced Non-Small Cell Lung Cancer

S. Agelaki, D. Mavroudis, C. Papadaki, 2021, Cells.

A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer.

S. Agelaki, V. Georgoulias, D. Mavroudis, 2001, Lung cancer.

Intrameningioma metastasis: A case-based literature review

A. Vakis, D. Mavroudis, Konstantin Bräutigam, 2021, Journal of Clinical Neuroscience.

Phase I Study of Vinorelbine and Carboplatin Combination in Patients with Taxane and Anthracycline Pretreated Advanced Breast Cancer

S. Agelaki, V. Georgoulias, N. Malamos, 2002, Oncology.

Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomiz

S. Agelaki, V. Georgoulias, D. Mavroudis, 2015, Lung cancer.

Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis.

Jeffery M. Meyer, Jack A. Taylor, A. Whittemore, 2018, International journal of epidemiology.

A network analysis to identify mediators of germline-driven differences in breast cancer prognosis

Gary D Bader, S. Cross, M. Beckmann, 2020, Nature Communications.

A network analysis to identify mediators of germline-driven differences in breast cancer prognosis

Gary D. Bader, Christine L. Clarke, Gary D Bader, 2020, Nature Communications.

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival

S. Cross, M. Lux, A. Olshan, 2023, Research square.

The impact of coding germline variants on contralateral breast cancer risk and survival

W. He, A. Børresen-Dale, N. Camp, 2023, American journal of human genetics.

Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial.

S. Agelaki, V. Georgoulias, A. Kalykaki, 2007, Lung Cancer.

Phase I study of weekly Docetaxel (D) and Gemcitabine (G) in advanced non-small cell lung cancer

V. Georgoulias, G. Samonis, D. Mavroudis, 2000 .

Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin.

V. Georgoulias, D. Mavroudis, J. Souglakos, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) combination in metastatic non-small cell lung cancer (NSCLC)

S. Agelaki, V. Georgoulias, G. Samonis, 1998 .

Clinical relevance of circulating CK-19 mRNA-positive cells detected during the period of adjuvant tamoxifen treatment in patients with early breast cancer

V. Georgoulias, M. Perraki, M. Kafousi, 2007 .

Abstract P1-04-08: Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer

S. Agelaki, G. Kallergi, V. Georgoulias, 2013 .

Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant Treatment

M. Tzardi, D. Mavroudis, J. Souglakos, 2021, Cancers.

Evaluation of the Role of Circulating Tumor Cells and Microsatellite Instability Status in Predicting Outcome of Advanced CRC Patients

M. Tzardi, D. Mavroudis, J. Souglakos, 2020, Journal of personalized medicine.

A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer

V. Georgoulias, N. Karachaliou, D. Mavroudis, 2012, Cancer Chemotherapy and Pharmacology.

Breast cancer risks associated with missense variants in breast cancer susceptibility genes

M. Beckmann, N. Camp, Jingmei Li, 2021, medRxiv.

Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer.

S. Agelaki, V. Georgoulias, A. Kalykaki, 2011, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Rare germline copy number variants (CNVs) and breast cancer risk

Jack A. Taylor, S. Cross, M. Beckmann, 2022, Communications Biology.

Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer

S. Agelaki, V. Georgoulias, I. Boukovinas, 2014, Cancer Chemotherapy and Pharmacology.

Front-Line Chemotherapy with Docetaxel and Gemcitabine Administered Every Two Weeks in Patients with Metastatic Breast Cancer: A Multicenter Phase II Study

V. Georgoulias, N. Malamos, D. Mavroudis, 2004, Oncology.

Salvage Treatment of Metastatic Breast Cancer with Docetaxel and Carboplatin

S. Agelaki, V. Georgoulias, N. Malamos, 2003, Oncology.

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).

V. Georgoulias, I. Boukovinas, N. Malamos, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

MicroRNAs Regulating Tumor and Immune Cell Interactions in the Prediction of Relapse in Early Stage Breast Cancer

Christoforos Nikolaou, S. Agelaki, D. Mavroudis, 2021, Biomedicines.

Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece.

K. Syrigos, G. Mountzios, D. Mavroudis, 2022, Future oncology.

A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.

V. Georgoulias, I. Boukovinas, N. Malamos, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Kallikrein 10 ( KLK 10 ) methylation as a novel prognostic biomarker in early breast cancer

E. Lianidou, E. Stathopoulos, V. Georgoulias, 2009 .

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome

M. Tzardi, E. Stathopoulos, D. Mavroudis, 2010, British Journal of Cancer.

Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer.

K. Syrigos, V. Georgoulias, N. Malamos, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter randomized phase III study comparing paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as front-line treatment in patients with small cell lung cancer (SCLC)

G. Samonis, N. Ziras, V. Georgoulias, 2000 .

Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).

S. Agelaki, V. Georgoulias, N. Malamos, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours

S. Agelaki, V. Georgoulias, M. Marselos, 2007, British Journal of Cancer.

Molecular detection of HER2 mRNA-positive cells in the peripheral blood of patients with operable breast cancer

G. Kallergi, V. Georgoulias, M. Perraki, 2005 .

Pertuzumab: a step forward in treating HER2-positive breast cancer

D. Mavroudis, 2012 .

A Dose-Escalation Study of Oxaliplatin and Vinorelbine in Patients with Advanced Solid Tumors

V. Georgoulias, D. Mavroudis, S. Kakolyris, 2002, Oncology.

Phase III trial of docetaxel (D) and carboplatin (CBDCA) as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC)

S. Agelaki, V. Georgoulias, N. Ziras, 1998 .

A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER.

V. Georgoulias, N. Malamos, D. Mavroudis, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MicroRNAs Regulating Tumor Immune Response in the Prediction of the Outcome in Patients With Breast Cancer

S. Agelaki, D. Mavroudis, C. Papadaki, 2021, Frontiers in Molecular Biosciences.

Significant Rise of Colorectal Cancer Incidence in Younger Adults and Strong Determinants: 30 Years Longitudinal Differences between under and over 50s

C. Lionis, D. Sifaki-Pistolla, D. Mavroudis, 2022, Cancers.

MicroRNAs involved in immune response as prognostic markers in early and metastatic breast cancer.

S. Agelaki, D. Mavroudis, K. Kalbakis, 2020 .

Clinical Outcomes Beyond 1L EGFR-TKI Progression in mNSCLC: Final Results of the Real-World Study ‘LUNGFUL’

M. Karamouzis, K. Syrigos, V. Georgoulias, 2023, AntiCancer Research.

A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy

V. Georgoulias, D. Mavroudis, I. Varthalitis, 2016, British Journal of Cancer.

Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report.

S. Agelaki, V. Georgoulias, G. Samonis, 2000, Seminars in oncology.

Immunohistochemical study of pElk-1 expression in human breast cancer: association with breast cancer biologic profile and clinicopathologic features.

E. Castanas, T. Vrekoussis, M. Kafousi, 2013, Breast.

A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer

K. Syrigos, S. Agelaki, V. Georgoulias, 2016, Cancer Chemotherapy and Pharmacology.

Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm

M. Dimopoulos, K. Koutsoukos, A. Bamias, 2022, Anti-cancer drugs.

Partial breast irradiation or whole breast radiotherapy for early breast cancer: A meta-analysis of randomized controlled trials.

D. Mavroudis, V. Georgoulias, G. Casazza, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group.

V. Georgoulias, A. Kalykaki, D. Mavroudis, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.

S. Agelaki, V. Georgoulias, A. Kalykaki, 2008, Lung cancer.

Rare copy number variants (CNVs) and breast cancer risk

Jack A. Taylor, S. Cross, M. Beckmann, 2021, bioRxiv.

Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer1

M. Tzardi, A. Voutsina, V. Georgoulias, 2017, Translational oncology.

Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study.

S. Agelaki, V. Georgoulias, N. Malamos, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study

K. Syrigos, K. Syrigos, G. Samonis, 2005, British Journal of Cancer.

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial

V. Georgoulias, A. Voutsina, D. Mavroudis, 2012, British Journal of Cancer.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study.

S. Agelaki, V. Georgoulias, I. Boukovinas, 2009, Lung cancer.

Salvage Chemotherapy with Gemcitabine and Oxaliplatin in Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Phase II Study

V. Georgoulias, N. Malamos, D. Mavroudis, 2006, Oncology.

Association of tumoral BRCA1, RRM1 and RRM2 mRNA expression levels with clinical responses to front-line docetaxel/gemcitabine (DG) chemotherapy in patients with non-small cell lung cancer (NSCLC)

V. Georgoulias, I. Boukovinas, E. Stathopoulos, 2008 .

The tAnGo fell short of inspiring the audience.

D. Mavroudis, 2017, The Lancet. Oncology.

Current Cardioprotective Strategies for the Prevention of Radiation-Induced Cardiotoxicity in Left-Sided Breast Cancer Patients

M. Tolia, D. Mavroudis, M. Mazonakis, 2023, Journal of personalized medicine.

ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.

I. Vlachonikolis, V. Georgoulias, D. Mavroudis, 2003, Lung cancer.

Baseline comprehensive geriatric assessment (CGA) and prediction of toxicity in elderly non-small cell lung cancer (NSCLC) patients receiving chemotherapy.

S. Agelaki, V. Georgoulias, Z. Giannousi, 2011, Journal of Clinical Oncology.

Dose Escalation Study on Oxaliplatin and Capecitabine (Xeloda) in Patients with Advanced Solid Tumors

S. Agelaki, V. Georgoulias, G. Samonis, 2004, Oncology.

The Prognostic Value of the Detection of Microbial Translocation in the Blood of Colorectal Cancer Patients

D. Mavroudis, J. Souglakos, M. Sfakianaki, 2020, Cancers.

Effect of adjuvant treatment on the circulating CK-19 mRNA-positive tumor cells in patients with early stage breast cancer.

V. Georgoulias, M. Perraki, E. Lianidou, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.

M. Tzardi, S. Agelaki, V. Georgoulias, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel

S. Rosset, W. He, S. Cross, 2023, Journal of Medical Genetics.

A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer

K. Syrigos, V. Georgoulias, N. Ziras, 2012, Cancer Chemotherapy and Pharmacology.

A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.

V. Georgoulias, S. Agelaki, A. Kalykaki, 2009, Journal of Clinical Oncology.

Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells.

K. Parker, A. Barrett, N. Hensel, 1996, Blood.

Spectrum and Frequency of Germline FANCM Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases

N. Camp, K. Czene, K. Humphreys, 2023, Cancers.

Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer

S. Agelaki, V. Georgoulias, M. Perraki, 2009, British Journal of Cancer.

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine

D. Mavroudis, I. Boukovinas, M. Taron, 2008, British Journal of Cancer.

Neuroendocrine tumors and CUP

A. Carrato, M. Kudo, R. Salazar, 2012 .

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

Jane E. Carpenter, W. Chung, M. Beckmann, 2019, npj Breast Cancer.

1459PCancer incidence and mortality trends in Crete, Greece during the last two decades (1992-2013): Results from the cancer registry of Crete

V. Georgoulias, N. Tzanakis, C. Lionis, 2017 .

First line treatment with docetaxel (D) and gemcitabine (G) in patients with inoperable pancreatic cancer: a multicenter phase II study

G. Fountzilas, D. Mavroudis, N. Tsavaris, 1999 .

Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis.

A. Valachis, D. Mauri, V. Georgoulias, 2011, Breast.

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.

S. Agelaki, G. Kallergi, V. Georgoulias, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients.

A. Makrigiannakis, A. Alegakis, G. Samonis, 2017, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Abstract P2-02-03: HER2 expression on circulating tumor cells before adjuvant chemotherapy and during follow-up in patients with HER2-negative early breast cancer

S. Agelaki, Harris Markomanolaki, G. Kallergi, 2016 .

Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

Kristen S Purrington, Jack A. Taylor, A. Whittemore, 2018, American Journal of Human Genetics.

Safety and immunogenicity of the optimized cryptic peptide TERT572Y in patients with advanced malignancies: A Phase I clinical study

I. Miconnet, M. Spiropoulou, P. Kanellou, 2005 .

Genome-wide association study of germline variants and breast cancer-specific mortality

A. Whittemore, W. Willett, S. Cross, 2019, British Journal of Cancer.

Unraveling the Role of Molecular Profiling in Predicting Treatment Response in Stage III Colorectal Cancer Patients: Insights from the IDEA International Study

M. Tzardi, P. Topalis, D. Mavroudis, 2023, Cancers.

Docetaxel in combination with gemcitabine (DG) versus docetaxel (D) as front-line treatment in patients with advanced/metastatic NSCLC: A multicentre, randomized, phase III trial

V. Georgoulias, K. Syrigos, G. Samonis, 2005 .

Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

Jack A. Taylor, S. Cross, C. Vachon, 2020, Genetic epidemiology.

LKB1 Loss Correlates with STING Loss and, in Cooperation with β-Catenin Membranous Loss, Indicates Poor Prognosis in Patients with Operable Non-Small Cell Lung Cancer

V. Georgoulias, K. Marias, A. Voutsina, 2024, Cancers.